Джейн Плант - Антирак груди

457

Grochowska, R. and others, 1999. Stimulated growth hormone (GH) release in Friesian cattle with respect to GH genotypes. Reproduction Nutrition Development, 39 (2), 171–180; Bourne, R.A. and others, 1977. Serum growth hormone concentrations after growth hormone or thyroid-releasing hormone in cows. Journal of Dairy Science, 60 (10), 1629–1635.

458

Chomczinsky, P. and others, 1993. Stimulatory effect of thyroid hormone on growth hormone gene expression in a human pituitary cell line. J. Clin. Endocrinol Metab, 77 (1), 281–285; Reynolds, A.M., 1991. The effects of chronic exposure to supra physiological concentrations of 3,5,3-triiodo-L-thyronine (T3) on cultured GC cells. Journal of Cellular. Physiology, 149 (3), 544–547.

459

Tenore, A. and others, 1980. Thyroidal response to peroral TSH in suckling and weaned rats. American Journal of Physiology, 238 (5), E428-430.

460

Slebodzinski, A.B. and others, 1998. Triiodothyronine (T3), insulin and characteristics of 5'-monodiodinase (5'-MD) in mare's milk from partarition to 21 days post-partum. Reproduction Nutrition Development, 38 (3), 235–244.

461

Fujimoto, N. and others, 1997. Upregulation of the estrogen receptor by triiodothyronine in rat pituitary cell lines. Journal of Steroid Biochemistry and Molecular Biology, 61 (1–2), 79–85.

462

Koldovsky, O., 1989. Search for the role of milk borne biologically active peptides for the suckling. J. Nutr., 119 (11), 1543–1551; Buts, J.P., 1998. Bioactive factors in milk. (in French.) Arch Pediatr, 5 (3), 298–306.

463

Faulkner, A., 1998. Insulin-like growth factor concentrations in milk and plasma after growth hormone treatment. Biochemical Society Transactions, 26 (4), S386; Baldini, E. and others, 1994. In vivo cytokinetic effects of recombinant human growth hormone (rhGH) in patients with advanced breast carcinoma. Journal of Biological Regulators and Homeostatic Agents, 8 (4), 113–116; Scheven, B.A. and others, 1991. Effects of recombinant human insulin-like growth factor-1 and -2 (IGF) and growth hormone (GH) on the growth of normal adult human osteoblast-like cells and human osteogenic sarcoma cells. Growth Regulation, 1 (4), 160–167; Hodate, K. and others, 1990, Plasma growth hormone, insuline-like growth factor-l, and milk production response to exogenous human growth hormone-releasing factor analogs in dairy cows. Endocrinologia Japonica, 37 (2), 261–273.

464

Koldovsky, O., 1989. Search for the role of milk borne biologically active peptides for the suckling. J. Nutr., 119 (11), 1543–1551; Buts, J.P., 1998. Bioactive factors in milk. (in French.) Arch Pediatr, 5 (3), 298–306.

465

Westrom, B.R. and others, 1987. Levels of immunoreactive insulin, neurotensin, and bombesin in porcine colostreum and milk. J. Pediatr. Gastroenterol. Nutr., 6 (3), 460–465; Ehman, R. and others, 1985. Bombesin, neurotensin and pro-gamma-melanotropin in immunoreactants in human milk. Regulatory Peptides, 10 (2–3), 99-105.

466

Shutt, D.A. and others, 1985. Comparison of total and free cortisol in bovine serum and milk colostreum. J. Dairy Set, 68 (7), 1832–1834.

467

Vaarala, O. and others, 1998. Cow milk feeding induces antibodies to insulin in children – a link: between cow milk and insulin-dependent diabetes mellitus? Scandinavian Journal of Immunology 47 (2), 131–135; Slebodzinsky, A.B. and others, 1998. Triiodothyronine (T3), insulin and characteristics of 5'-monodiodinase (5'-MD) in mare's milk from partarition to 21 days post-partum. Reprod Nutr Dev, 38 (3), 235–244; Westrom, B.R. and others, 1987. Levels of immunoreactive insulin, neurotensin, and bombesin in porcine colostreum and milk. J. Pediatr Gastroenterol Nutr., 6 (3), 460–465.

468

Ferrando, T. and others, 1990. Beta-endorphin-like and alpha-MSH-like immunoreactivities in human milk. Life Sci, 47 (7), 633–635.

469

http://www.13.waisays.com/cancer2.htm; Newcomb, P.A. and Egan, K.M., 2006. Dairy food and ovarian cancer risk. The Lancet, March 2006, 797–799; Stang, A. and others, 2006. Adolescent milk fat and galactose consumption and testicular germ cell cancer. Cancer Epidemiology and Biomarkers Prevention, 15, 2189–2195.

470

Maruuchi, T. and others, 1998. Effects of gonadotropin-releasing hormone agonist on rat ovarian adenocarcinoma cell lines in vitro and in vivo. Japanese Journal of Cancer Research, 89 (9), 977–983; Kuroda, H. and others, 1998. Human chorionic gonadotrophin (hCG) inhibits cisplatin-induced apoptosis in ovarian cancer cells: possible role of up-regulation of IGF-1 by hCG. Int J. Cancer, 76 (4), 571–578; Kurbacher, C.M. and others, 1995. Influence of luteinising hormone on cell growth and CA 125 secretion of primary epithelial ovarian carcinomas in vitro. Tumour Biology, 16 (6), 374–384; Manetta, A. and others, 1995. Inhibition of growth of human ovarian cancer in nude mice by luteinising hormone-releasing hormone antagonist Cetrorelix (SB-75). Fertility and Sterility, 63 (2), 282–287.

471

Reiter, E. and others, 1999. Effects of pituitary hormones on the prostate. Prostate, 38 (2), 159–165; Lamharzi, N. and others, 1998. Luteinising hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF– 2 in tumors. Regulatory Peptides, 77 (113), 185–192; Jungwirth, A. and others, 1997. Luteinising hormone-releasing hormone (LH-RH) antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-2 inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. Prostate, 32 (3), 164–172; Maezawa, H. and others, 1997. Potentiating effect of buserelin acetate, an LHRH agonist on the proliferation of ventral prostatic epithelial cells in testosterone-treated castrated rats. Int J. Urol, 4 (4), 411–416; Using, A.W. and others, 1993. Serological precursors of cancer serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev, 2 (1), 27–32; Garde, S. and others, 1993. Effect of prostatic inhibiting peptide on prostate cancer cell growth in vitro and in vivo. Prostate, 7 (2), 183–194.

472

Bosland, M.C., 1996. Hormonal factors in carcinogenesis of the prostate and testis in humans and in animal models. Progress in Clinical and Biological Research, 394, 309–352.

473

Chapman, S. and others, 1992. Changes in adult cigarette consumption per head in 128 countries, 1986–1990. Tobacco Control, 1, 281–284.

474

http://www.who.int

475

Chapman, S. and others, 1992. Changes in adult cigarette consumption per head in 128 countries, 1986–1990. Tobacco Control, 1. 281–284.

476

http://www.who.int

477

http://www.13.waisays.com/cancer2.htm

478

Underwood, L.E., D'Ercole, J.A. and Van Wyk, J.J., 1980. Somatomedin-C and the assessment of growth. Ped. Clin. N Amer, 27, 4, 771–782, and Perdue, J.F. 1984. Chemistry, structure and function of insulin-like growth factors and their receptors: a review. Can J. Biochem Cell Bio, 62, 1237–1245.

479

http://www.com/healthnews/milk.html

480

Pollack, Michael, 2003. Cancer, aging and IGF physiology. Meeting of the Royal Society of Medicine in London in October 2003, entitled «Biology of IGF-I: its interaction with insulin in health and malignant states».

481

Lonning, Per Eystein, 2003. IGF-I and breast cancer. Meeting of the Royal Society of Medicine in London in October 2003, entitled «Biology of IGF-I: its interaction with insulin in health and malignant states».

482

Yee, Doug, 2003. Targeting the IGF system for anti-tumour therapy. Meeting of the Royal Society of Medicine in London in October 2003, entitled «Biology of IGF-I: its interaction with insulin in health and malignant states».

483

Pollack, Michael, 2003. Cancer, aging and IGF physiology. Meeting of the Royal Society of Medicine in London in October 2003, entitled «Biology of IGF-I; its interaction with insulin in health and malignant states».

484

Holly, Jeff, 1998. Insulin-like growth factor-1 and new opportunities for cancer prevention. Lancet, 351, 9113, 9 May, 1373–1375.

485

Chan, J.M., Stampfer, M.J., Giovannucci, E. and others, 1998. Plasma insulin-like growth factor-I and prostate cancer risk; a prospective study. Science, 279, 563–566; Harman, S.M., Metter, E.J., Blackmail, M.R., Landis, P.K. and Carter, H.B., 2000. Serum levels of insulin-type growth factor 1 (IGF-I), IGF II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J. Clin. Endocrinol Metab., 85, 4258–4265; Stattin, P. and nine others, 2000. Plasma insulin-like growth factor-I insulin-like growth-binding proteins, and prostate cancer risk: a prospective study. J. Natl. Cancer Inst., 92, 1910–1917; Chokkalingam, A.P, and 12 others, 2001. Insulinlike growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev., 10, 421–427; Chan, J.M., Stampfer, M.J., Ma, J. and others, 2002. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J. Natl Cancer Inst, 94, 1099–1106; Mantzoros, C.S., Tzonou, A., Signorello, L.B. and others, 1997. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. British Journal of Cancer, 76, 1115–1118; Wolk, A., Mantzoros, C.S., Andersson, S.O. and others, 1998. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J. Natl Cancer Inst, 90, 911–915; Holly, J.M.P., Gunnell, D.J. and Davey Smith., G, 1999. Growth hormone, IGF-1 and cancer. Less intervention. Less intervention to avoid cancer? More intervention to prevent cancer. J. Endocrinol, 162, 321–330.